一篇具有里程碑意义的论文,介绍了髓瘤中蛋白酶抑制的方法
Anup Joseph Devasia1, Guido Lancman1, A Keith Stewart1
1Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Cancer research
|October 2, 2023
概括
发现诸如博尔特佐米布之类的蛋白酶体抑制剂,彻底改变了多发性骨髓瘤治疗. 这些向疗法通过抑制蛋白质降解,显著改善了患者的生存率,并改变了疾病管理.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 2000年代初标志着多发性骨髓瘤护理的治疗革命.
- 关键的发现包括thalidomide的有效性和蛋白质酶抑制剂的发展.
- 这些疗法准了无处不在的蛋白质降解,显著改善了患者的生存率.
研究的目的:
- 为了研究蛋白质酶抑制在多发性骨髓瘤中的作用.
- 在多发性骨髓瘤的临床前模型中证明PS-341 (博特佐米布) 的疗效.
- 为了在多发性骨髓瘤管理中建立一个范式的转变.
主要方法:
- 在血液恶性瘤中探索蛋白质酶抑制剂PS-341的临床前研究.
- 在人体多发性骨髓瘤细胞上的体外实验.
- 临床试验评估临床前发现的相关性.
主要成果:
- PS-341 (博特佐米布) 显示出显著的临床有效性.
- 蛋白质酶抑制剂抑制了髓瘤细胞的生长并诱导了细胞的亡.
- 在人类多发性髓瘤细胞中,PS-341克服了药物耐药性.
结论:
- 蛋白质酶抑制剂代表了多发性骨髓瘤治疗中的范式转变.
- 针对性疗法,如博尔特佐米布,已经大大延长了患者的存活时间.
- 这项研究改变了全球多发性骨髓瘤的管理.
相关概念视频
The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome Structure
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...


